Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-585-0 | CAS number: 12013-46-6
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
The key study for skin sensitisation potential of Calcium stannate was tested in a Local Lymph Node Assay (LLNA) with CBA/Ca mice and 5-bromo-deoxyuridine (BrdU (OECD No. 442B) (Hey S., 2010).The test substance was applied as 10 % (w/w), 25 % (w/w) and 50 % (w/w) preparation in vehicle, next to anegative control group treated with 50% propylene glycol (NC) and a positive control group (PC) treated with 25 % (v/v) hexyl cinnamic aldehyde (HCA) in acetone/olive oil (3+1). Four animals per group were treated.25 µL of the selected test substance preparation, reference substance, or vehicle have been applied to the dorsal side of each ear for three consecutive days. No treatment took place on day 4.On day 5 each mouse received BrdU-solution injected intraperitoneally. The animals were sacrificed on day 6 and the draining auricular lymph node from each mouse ear was exercised. A single-cell suspension of the lymph node cells was prepared separately for each animal.
Body weight development of the animals was as expected and within normal ranges. Increases of the ear thickness following test substance application indicating strong irritation properties or symptoms of systemic toxicity were not observed. Only slight symptoms of local irritation at the ears of the highest test substance concentration group and the positive control group were observed.For each treatment group the mean Stimulation Index SI was calculated from the BrdU-labelling indices for each mouse. The Stimulation Indices for Calcium Stannate were lower than 1.6 for all tested concentrations. The positive control showed a clear positive response (SI≥1.6) indicating the adequate function of the test system. From the test results it is concluded that the test substance Calcium stannate has no sensitising properties under the given experimental conditions.
Migrated from Short description of key information:
The test substance Calcium Stannate was tested regarding its skin sensitisation potential in a Local Lymph Node Assay (LLNA) with CBA/Ca mice and 5-bromo-deoxyuridine (BrdU) to measure lymphocyte proliferationa (OECD No. 442B). From the test results it is concluded that the test substance Calcium stannate has no sensitising properties under the given experimental conditions.
Justification for classification or non-classification
As there is no sensitisation potential in the LLNA test, classification is not warranted.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
